{
    "clinical_study": {
        "@rank": "42009", 
        "arm_group": [
            {
                "arm_group_label": "Sarilumab - dose 1", 
                "arm_group_type": "Experimental", 
                "description": "Single subcutaneous (SC) injection of Sarilumab, dose 1, plus methotrexate background treatment (dispensed and dosed according to local practice)"
            }, 
            {
                "arm_group_label": "Sarilumab - dose 2", 
                "arm_group_type": "Experimental", 
                "description": "Single SC injection of Sarilumab, dose 2, plus methotrexate background treatment (dispensed and dosed according to local practice)"
            }, 
            {
                "arm_group_label": "Tocilizumab - dose 1", 
                "arm_group_type": "Active Comparator", 
                "description": "Single intravenous (IV) administration of Tocilizumab, dose 1, plus methotrexate background treatment (dispensed and dosed according to local practice)"
            }, 
            {
                "arm_group_label": "Tocilizumab - dose 2", 
                "arm_group_type": "Active Comparator", 
                "description": "Single IV administration of Tocilizumab, dose 2, plus methotrexate background treatment (dispensed and dosed according to local practice)"
            }
        ], 
        "brief_summary": {
            "textblock": "The main purposes of this study are to describe the pharmacodynamic effects, safety and\n      pharmacokinetics of a single dose of sarilumab."
        }, 
        "brief_title": "Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Rheumatoid Arthritis", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patients with RA as defined by the 2010 revised American College of Rheumatology\n             (ACR)\n\n          2. ACR Class I-II functional status, based on the 1991 revised criteria\n\n          3. Treated for a minimum of 12 weeks with Methotrexate with a stable dose of MTX for at\n             least 8 weeks prior to screening visit\n\n        Exclusion Criteria:\n\n          1. Patients less than 18 years of age or minimum legal age\n\n          2. Prior treatment with any biologic anti-Interleukin 6 (IL-6) or IL-6 Receptor (IL-6R)\n             antagonists\n\n          3. Use of parenteral corticosteroids or intra-articular corticosteroids within 4 weeks\n             prior to screening\n\n          4. Use of oral corticosteroids in a dose higher than prednisone 10 mg or equivalent per\n             day, or a change in dosage within 4 weeks prior to randomization\n\n          5. Participation in any clinical research study that evaluated an investigational drug\n             or therapy within 5 half-lives or 60 days of the screening visit, whichever is longer\n\n          6. Treatment with oral/ biologic DMARDs (disease-modifying antirheumatic drugs), other\n             than MTX, within a certain amount of time prior to screening visit\n\n          7. Active or suspected TB or at high risk of contracting TB\n\n          8. Fever, or chronic, persistent, or recurring infections requiring active treatment\n\n          9. HIV positive\n\n        Note: The above information is not intended to contain all considerations relevant to a\n        patient's potential participation in a clinical trial therefore not all inclusion/\n        exclusion criteria are listed."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 3, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02097524", 
            "org_study_id": "6R88-RA-1309"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Sarilumab - dose 1", 
                    "Sarilumab - dose 2"
                ], 
                "intervention_name": "Sarilumab", 
                "intervention_type": "Drug", 
                "other_name": [
                    "REGN88", 
                    "SAR153191"
                ]
            }, 
            {
                "arm_group_label": [
                    "Tocilizumab - dose 1", 
                    "Tocilizumab - dose 2"
                ], 
                "intervention_name": "Tocilizumab", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "March 26, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Miami", 
                    "country": "United States", 
                    "state": "Florida"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "overall_contact": {
            "email": "clinicaltrial@regeneron.com", 
            "last_name": "Clinical Trials Administrator"
        }, 
        "overall_official": {
            "affiliation": "Regeneron Pharmaceuticals", 
            "last_name": "Clinical Trial Management", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Pharmacodynamic (PD) parameters, what a drug does to the body, will be collected from baseline through week 4:\nthe time to nadir (or peak)\nchange from baseline\narea under the curve (AUC)", 
            "measure": "PD parameters", 
            "safety_issue": "No", 
            "time_frame": "baseline through week 4"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02097524"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Percentage of patients with treatment-emergent adverse events (TEAEs) from baseline through end of study (week 6).", 
                "measure": "Percentage of TEAEs", 
                "safety_issue": "Yes", 
                "time_frame": "baseline through week 6"
            }, 
            {
                "description": "Pharmacokinetic (PK) parameters, what the body does to a drug, will be collected from baseline through week 4:\nAUC\nCL (clearance)\nCmax (the peak concentration)\nt1/2 (observed terminal half-life)", 
                "measure": "PK parameters", 
                "safety_issue": "No", 
                "time_frame": "baseline through week 4"
            }
        ], 
        "source": "Regeneron Pharmaceuticals", 
        "sponsors": {
            "collaborator": {
                "agency": "Sanofi", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Regeneron Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}